Cellmid was not able to interest Large Pharmaceutical Companies in Lyramid. Whether that was because of the seller (Cellmid) or the product (Lyramid-Midkine, Midkine blocking), I don't know. Nobody outside Cellmid or those Companies would know.
If it was the product, since that is being planned to stay the same, then I can't see a change in interest.
Being blunt,if it was the seller, Roquefort Therapeutics management would not be publicly perceived to be an improvement on Cellmid management. Therefore, I don't see a change in interest there either.
So , IMO whatever Roquefort/Randox or others do regarding diagnostic Midkine, it will not lead to Large Pharmaceutical Company interest in Midkine blocking or anything else called Midkine.
